Not enough data
Briana's coverage primarily focuses on healthcare and medical advancements, often citing data to support her articles. She is particularly interested in stories related to healthcare technology, medical research, treatments, and disparities within the healthcare system.
Given her reliance on data and expert commentary, Briana would likely be receptive to pitches from professionals with expertise in these areas. This could include researchers or practitioners who can provide insights supported by reliable data or those actively working towards addressing healthcare disparities.
As Briana does not have a specific geographic focus mentioned, she appears open to covering global as well as national developments within the healthcare sector.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Briana Contreras
Today at the annual Asembia Specialty Summit in Las Vegas, Sarah Marche, VP of Pharmacy at Highmark Health, spoke alongside other professionals from various stakeholders within the industry who are invested some way in digital therapeutics.
By: Briana Contreras
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization's innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
By: Briana Contreras
Tony Little, ND, VP of Solutions Architecture at Prescryptive Health, shares how the organization is tackling one of the biggest barriers to prescription adherence — cost — through a digital app, among the other barriers patients face.
By: Briana Contreras
Managed Healthcare Executive had a conversation with Kelly Chillingworth, RPh, director of business development at RxBenefits this week about the unique connection between pharmacy and telemedicine, what impact telemedicine & its pharmacy costs have on self-funded employers and how the right virtual care services a health provider offers to their members can be essential to building a competitive benefit.
By: Peter Wehrwein, Briana Contreras
The five states have moved to prohibit accumulators and maximizers as the federal government takes a hands-off approach, according to John “Jack” S. Linehan, a lawyer at Epstein Becker Green, who is featured in this second part of a two-part video series.
By: Briana Contreras
Kelsey Lang, principal of Avalere, breaks down the three provisions of the Inflation Reduction Act, which was discussed today at the annual Asembia Specialty Pharmacy Summit in Las Vegas.
By: Briana Contreras
Briana Contreras, associate editor of Managed Healthcare Executive, spoke with Josh Benner, founder and CEO of RxAnte, in this latest episode of Tuning In to the C-Suite podcast. In the conversation, Benner addressed the issue of medication misuse among patients based on access, demographics and more, as well as its solutions. The two also talked about the role technology has on the future of pharmacy and how solutions provided through RxAnte can assist plans to improve their CMS Start rating measures.
By: Briana Contreras
Cate Lockhart, executive director of the Biologics and Biosimilars Collective Intelligence Consortium, shared results yesterday of a survey that look at biosimilars on the pharmacy benefit side of coverage versus medical benefit. The survey also shared how payers and those on the pharmaceutical side are anticipating the introduction of Adalimumab (Humira®), as well as what to look for in the future of the biosimilar pipeline.
By: Peter Wehrwein, Briana Contreras
In this part three video series, Civica Rx CEO Martin VanTrieste says Civica is launching an outpatient retail market with its first retail drug coming to the market next year.
By: Briana Contreras
A draft ICER report found that baxdrostat and lorundrostat don't lower blood pressure more than older generics but do cost much more.
